Cited by 84

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer

Cekaite, Lina, Eide, Peter W., Lind, Guro E., Skotheim, Rolf I., Lothe, Ragnhild A.·2016·Oncotarget

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.6390

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC BY · PubMed Central
Figure 1 An overview of miRNA studies in colorectal cancer (CRC) A. A rapid growth of the published research reports illustrated by the number of studies (with and without clinical samples) per year; the box plots represent numbers of the analyzed patient samples per year; B. The proportion of studies reporting aberrant miRNA (expression) and miRNA regulation by copy number variation (CNV), miRNAs regulated by epigenetic modifications, miRNA regulation by transcription factors (TF); single nucleotide polymorphism (SNP) in miRNA coding genes or binding sites of their target genes. C. The quantity of patient cohorts segregated by the type of analysis performed.
Figure 1 An overview of miRNA studies in colorectal cancer (CRC) A. A rapid growth of the published research reports illustrated by the number of studies (with and without clinical samples) per year; the box plots represent numbers of the analyzed patient samples per year; B. The proportion of studies reporting aberrant miRNA (expression) and miRNA regulation by copy number variation (CNV), miRNAs regulated by epigenetic modifications, miRNA regulation by transcription factors (TF); single nucleotide polymorphism (SNP) in miRNA coding genes or binding sites of their target genes. C. The quantity of patient cohorts segregated by the type of analysis performed.CC BY · PubMed Central
Figure 2 Main miRNA research themes in colorectal cancer (CRC) studies A. The trends of miRNA research themes exemplified by article keywords. B. An illustration and a heatmap of miRNAs validated to regulate CDH1, its regulators and other mesenchymal markers in CRC. The miRNA/mRNA was obtained from CRC patients registered in TCGA. values represent RPM normalized, median-centered values (for further information see Supplementary Material).
Figure 2 Main miRNA research themes in colorectal cancer (CRC) studies A. The trends of miRNA research themes exemplified by article keywords. B. An illustration and a heatmap of miRNAs validated to regulate CDH1, its regulators and other mesenchymal markers in CRC. The miRNA/mRNA was obtained from CRC patients registered in TCGA. values represent RPM normalized, median-centered values (for further information see Supplementary Material).CC BY · PubMed Central
Figure 3 MiRNA regulation of target genes A. and B. The most frequently validated miRNA and target genes. C. The enlarged leading miRNA-targets nodes generated using the validated miRNA-target pairs. The network edges are coded by degree of expressional miRNA-mRNA associations obtained in TCGA CRC patients. MiRNA nodes are indicated by rectangles, target nodes as ovals. Size of nodes reflects the number of connections, with bigger nodes representing more densely connected regions. The node of miR-143/miR-145-KRAS should be taken with precaution in light of the recent results by Chivukala et. al.[105].
Figure 3 MiRNA regulation of target genes A. and B. The most frequently validated miRNA and target genes. C. The enlarged leading miRNA-targets nodes generated using the validated miRNA-target pairs. The network edges are coded by degree of expressional miRNA-mRNA associations obtained in TCGA CRC patients. MiRNA nodes are indicated by rectangles, target nodes as ovals. Size of nodes reflects the number of connections, with bigger nodes representing more densely connected regions. The node of miR-143/miR-145-KRAS should be taken with precaution in light of the recent results by Chivukala et. al.[105].CC BY · PubMed Central
Figure 4 An overview of key signaling pathways in CRC and the regulation of their components by miRNAs MiRNAs that are involved in multiple pathways and contribute to the cross-talk among the pathways are marked in bold.
Figure 4 An overview of key signaling pathways in CRC and the regulation of their components by miRNAs MiRNAs that are involved in multiple pathways and contribute to the cross-talk among the pathways are marked in bold.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 296

  1. Bray, 2013, Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, Eur J Cancer, 49, 1374, 10.1016/j.ejca.2012.12.027 · DOI
  2. Stewart, Wild. World Cancer Report. 2014. · DOI
  3. Bartel, 2009, Most mammalian mRNAs are conserved targets of microRNAs, Genome Res, 19, 92, 10.1101/gr.082701.108 · DOI · Paper page
  4. Griffiths-Jones, 2014, miRBase: annotating high confidence microRNAs using deep sequencing data, Nucleic Acids Research, 42, D68, 10.1093/nar/gkt1181 · DOI · Paper page
  5. Fulmer-Smentek, 2014, Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study, Nat Methods, 11, 809, 10.1038/nmeth.3014 · DOI · Paper page
  6. Cohen, 2003, bantam Encodes a Developmentally Regulated microRNA that Controls Cell Proliferation and Regulates the Proapoptotic Gene hid in Drosophila, Cell, 113, 25, 10.1016/S0092-8674(03)00231-9 · DOI · Paper page
  7. Bartel, 2004, MicroRNAs Modulate Hematopoietic Lineage Differentiation, Science, 303, 83, 10.1126/science.1091903 · DOI · Paper page
  8. Ambros, 1993, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, Cell, 75, 843, 10.1016/0092-8674(93)90529-Y · DOI · Paper page
  9. Fishman, 2000, Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA, Nature, 408, 86, 10.1038/35040556 · DOI
  10. Negrini, 2002, Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc Natl Acad Sci U S A, 99, 15524, 10.1073/pnas.242606799 · DOI · Paper page
  11. James, 2003, Reduced accumulation of specific microRNAs in colorectal neoplasia, Mol Cancer Res, 1, 882
  12. Takahashi, 2004, Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival, Cancer Res, 64, 3753, 10.1158/0008-5472.CAN-04-0637 · DOI
  13. Mendell, 2005, c-Myc-regulated microRNAs modulate E2F1 expression, Nature, 435, 839, 10.1038/nature03677 · DOI · Paper page
  14. Ashkenazi, 2012, A second-generation microRNA-based assay for diagnosing tumor tissue origin, Oncologist, 17, 801, 10.1634/theoncologist.2011-0466 · DOI
  15. Tuschl, 2003, A uniform system for microRNA annotation, RNA, 9, 277, 10.1261/rna.2183803 · DOI · Paper page
  16. Calin, 2009, SnapShot: MicroRNAs in Cancer, Cell, 137, 586, 10.1016/j.cell.2009.04.040 · DOI
  17. Mendell, 2014, Tumor suppression by miR-26 overrides potential oncogenic activity in intestinal tumorigenesis, Genes Dev, 28, 2585, 10.1101/gad.250951.114 · DOI
  18. Garcia De Herreros, 2000, The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells, Nat Cell Biol, 2, 84, 10.1038/35000034 · DOI
  19. Foisner, 2005, DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells, Oncogene, 24, 2375, 10.1038/sj.onc.1208429 · DOI
  20. Christofori, 1998, A causal role for E-cadherin in the transition from adenoma to carcinoma, Nature, 392, 190, 10.1038/32433 · DOI
  21. Hermeking, 2011, miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions, Cell Cycle, 10, 4256, 10.4161/cc.10.24.18552 · DOI
  22. Sarkar, 2012, Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF, J Hematol Oncol, 5, 58, 10.1186/1756-8722-5-58 · DOI
  23. Hermeking, 2013, SNAIL, miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition, EMBO J, 32, 3079, 10.1038/emboj.2013.236 · DOI
  24. Hermeking, 2013, Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and beta-catenin predicts distant metastasis of colon cancer, Clin Cancer Res, 19, 710, 10.1158/1078-0432.CCR-12-1703 · DOI
  25. Yu, 2015, miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer, Oncogene, 34, 4142, 10.1038/onc.2014.348 · DOI
  26. Song, 2015, Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil, Mol Med Rep, 11, 577, 10.3892/mmr.2014.2726 · DOI
  27. Brabletz, 2008, A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells, EMBO Rep, 9, 582, 10.1038/embor.2008.74 · DOI
  28. Sansom, 2009, The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs, Nat Cell Biol, 11, 1487, 10.1038/ncb1998 · DOI
  29. Wang, 2012, miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1, Clin Exp Metastasis, 29, 457, 10.1007/s10585-012-9463-7 · DOI
  30. Esteller, 2012, Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis, Oncogene, 31, 2062, 10.1038/onc.2011.383 · DOI
  31. Goodall, 2013, Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression, Neoplasia, 15, 180, 10.1593/neo.121828 · DOI
  32. Goel, 2013, MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis, Gut, 62, 1315, 10.1136/gutjnl-2011-301846 · DOI
  33. Li, 2014, miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer, Mol Cancer Ther, 13, 3137, 10.1158/1535-7163.MCT-14-0167 · DOI
  34. Weitz, 2011, Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases, Cancer Sci, 102, 1799, 10.1111/j.1349-7006.2011.02023.x · DOI
  35. Hung, 2012, Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9, Clin Cancer Res, 18, 6416, 10.1158/1078-0432.CCR-12-0832 · DOI
  36. Skotheim, 2012, MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer, Neoplasia, 14, 868, 10.1593/neo.121094 · DOI
  37. Cancer Genome Atlas Network, 2012, Comprehensive molecular characterization of human colon and rectal cancer, Nature, 487, 330, 10.1038/nature11252 · DOI · Paper page
  38. Li, 2015, MiR-361-5p inhibits colorectal and gastric cancer growth and metastasis by targeting staphylococcal nuclease domain containing-1, Oncotarget, 6, 17404, 10.18632/oncotarget.3744 · DOI
  39. Xi, 2011, Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis, Nat Commun, 2, 554, 10.1038/ncomms1555 · DOI
  40. Nakagama, 2012, miR-493 induction during carcinogenesis blocks metastatic settlement of colon cancer cells in liver, EMBO J, 31, 1752, 10.1038/emboj.2012.25 · DOI
  41. Tavazoie, 2015, Extracellular metabolic energetics can promote cancer progression, Cell, 160, 393, 10.1016/j.cell.2014.12.018 · DOI · Paper page
  42. Zhang, 2014, Potential microRNA-mediated oncogenic intercellular communication revealed by pan-cancer analysis, Sci Rep, 4, 7097, 10.1038/srep07097 · DOI
  43. Adachi, 2014, Association of microRNA-31 with BRAF mutation, colorectal cancer survival, serrated pathway, Carcinogenesis, 35, 776, 10.1093/carcin/bgt374 · DOI
  44. Ren, 2013, A microRNA panel to discriminate carcinomas from high-grade intraepithelial neoplasms in colonoscopy biopsy tissue, Gut, 62, 280, 10.1136/gutjnl-2011-301554 · DOI
  45. Brenner, 2012, Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer, Int J Oncol, 40, 2097
  46. Glimelius, 2014, EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum, Eur J Cancer, 50, e1
  47. He, 2013, Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis, Lancet Oncol, 14, 1295, 10.1016/S1470-2045(13)70491-1 · DOI
  48. Jung, 2015, Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse, BMC Gastroenterol, 15, 2, 10.1186/s12876-015-0227-0 · DOI
  49. Monzo, 2014, Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines, J Surg Oncol, 109, 676, 10.1002/jso.23572 · DOI
  50. Wang, 2013, Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value, Int J Colorectal Dis, 28, 697, 10.1007/s00384-013-1674-0 · DOI
  51. Hernando, 2011, Efficient in vivo microRNA targeting of liver metastasis, Oncogene, 30, 1481, 10.1038/onc.2010.523 · DOI
  52. Qin, 2012, miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer, Gut, 61, 1447, 10.1136/gutjnl-2011-301122 · DOI
  53. Ding, 2015, Radiation-induced microRNA-622 causes radioresistance in colorectal cancer cells by down-regulating Rb, Oncotarget, 6, 15984, 10.18632/oncotarget.3762 · DOI
  54. Crino, 2014, MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies, Clin Colorectal Cancer, 13, e34
  55. Hoefler, 2014, miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor, J Clin Pathol, 67, 198, 10.1136/jclinpath-2013-201904 · DOI
  56. Kuwano, 2015, MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation, Carcinogenesis, 36, 338, 10.1093/carcin/bgu242 · DOI
  57. Galandiuk, 2012, Plasma miR-21: a potential diagnostic marker of colorectal cancer, Ann Surg, 256, 544, 10.1097/SLA.0b013e318265bd6f · DOI
  58. Hernandez, 2015, Differential MIR-21 expression in plasma from mesenteric versus peripheral veins: an observational study of disease-free survival in surgically resected colon cancer patients, Medicine (Baltimore), 94, e145, 10.1097/MD.0000000000000145 · DOI
  59. Lin, 2010, Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression, J Gastroenterol Hepatol, 25, 1674, 10.1111/j.1440-1746.2010.06417.x · DOI
  60. Ding, 2015, Diagnostic value of circulating miR-21 for colorectal cancer: a meta-analysis, Cancer Biomark, 15, 47, 10.3233/CBM-140437 · DOI
  61. Sung, 2009, Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening, Gut, 58, 1375, 10.1136/gut.2008.167817 · DOI · Paper page
  62. Zhu, 2013, A plasma microRNA panel for early detection of colorectal cancer, Int J Cancer, 136, 152
  63. Dang, 2015, Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer, Cancer Biol Ther, 16, 268, 10.1080/15384047.2014.1002327 · DOI
  64. Fassan, 2014, Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression, Oncotarget, 5, 6611, 10.18632/oncotarget.2245 · DOI
  65. Kure, 2014, Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment, Mol Oncol, 8, 59, 10.1016/j.molonc.2013.09.001 · DOI
  66. Matsumura, 2013, Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test, Cancer Epidemiol Biomarkers Prev, 22, 1844, 10.1158/1055-9965.EPI-13-0512 · DOI
  67. Matsumura, 2010, MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening, Cancer Prev Res (Phila), 3, 1435, 10.1158/1940-6207.CAPR-10-0036 · DOI
  68. Yu, 2014, MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma, Oncotarget, 5, 12083, 10.18632/oncotarget.2499 · DOI
  69. Mori, 2014, MicroRNA-29b is a Novel Prognostic Marker in Colorectal Cancer, Ann Surg Oncol, 12, 1
  70. Yoshida, 2010, Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells, Int J Cancer, 127, 1072, 10.1002/ijc.25143 · DOI
  71. Gibbs, 2014, Functional screening identifies miRNAs influencing apoptosis and proliferation in colorectal cancer, PLoS One, 9, e96767, 10.1371/journal.pone.0096767 · DOI
  72. Kuiper, 2011, Identification of candidate predisposing copy number variants in familial and early-onset colorectal cancer patients, Int J Cancer, 129, 1635, 10.1002/ijc.25821 · DOI
  73. Scorilas, 2014, Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients, Clin Chem Lab Med, 52, 1217
  74. Smyrk, 2009, Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states, BMC Cancer, 9, 401, 10.1186/1471-2407-9-401 · DOI
  75. Bortoluzzi, 2013, Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis, BMC Genomics, 14, 589, 10.1186/1471-2164-14-589 · DOI
  76. Ding, 2014, microRNA-182 targets special AT-rich sequence-binding protein 2 to promote colorectal cancer proliferation and metastasis, J Transl Med, 12, 109, 10.1186/1479-5876-12-109 · DOI
  77. Russo, 2013, Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?, Expert Opin Ther Targets, 17, 1249, 10.1517/14728222.2013.832206 · DOI
  78. Subramanian, 2014, Sequential expression of miR-182 and miR-503 cooperatively targets FBXW7, contributing to the malignant transformation of colon adenoma to adenocarcinoma, J Pathol, 234, 488, 10.1002/path.4407 · DOI
  79. Vogelstein, 1997, Genetic instability in colorectal cancers, Nature, 386, 623, 10.1038/386623a0 · DOI
  80. Perucho, 1994, Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation, Nat Genet, 6, 273, 10.1038/ng0394-273 · DOI
  81. Issa, 1999, CpG island methylator phenotype in colorectal cancer, Proc Natl Acad Sci U S A, 96, 8681, 10.1073/pnas.96.15.8681 · DOI
  82. Skotheim, 2011, Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival, Genome Med, 3, 32, 10.1186/gm248 · DOI
  83. Negrini, 2007, mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer, Mol Cancer, 6, 54, 10.1186/1476-4598-6-54 · DOI
  84. Hamilton, 2010, Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma, J Mol Diagn, 12, 433, 10.2353/jmoldx.2010.090154 · DOI
  85. Nuovo, 2010, Modulation of mismatch repair and genomic stability by miR-155, Proc Natl Acad Sci U S A, 107, 6982, 10.1073/pnas.1002472107 · DOI
  86. Llor, 2011, Colorectal cancers with microsatellite instability display unique miRNA profiles, Clin Cancer Res, 17, 6239, 10.1158/1078-0432.CCR-11-1424 · DOI
  87. Wheeler, 2013, MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes, J Pathol, 229, 99, 10.1002/path.4087 · DOI
  88. Laurberg, 2013, Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer, Int J Cancer, 132, 2303, 10.1002/ijc.27921 · DOI
  89. Duval, 2013, Overexpression of microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases, Carcinogenesis, 34, 828, 10.1093/carcin/bgs408 · DOI
  90. Han, 2015, Elevated microRNA-23a Expression Enhances the Chemoresistance of Colorectal Cancer Cells with Microsatellite Instability to 5-Fluorouracil by Directly Targeting ABCF1, Curr Protein Pept Sci, 16, 301, 10.2174/138920371604150429153309 · DOI
  91. Croce, 2010, MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2), Proc Natl Acad Sci U S A, 107, 21098, 10.1073/pnas.1015541107 · DOI
  92. Lesuffleur, 2012, MiRNA genes constitute new targets for microsatellite instability in colorectal cancer, PLoS One, 7, e31862, 10.1371/journal.pone.0031862 · DOI
  93. Croce, 2004, Human microRNA genes are frequently located at fragile sites, genomic regions involved in cancers, Proc Natl Acad Sci U S A, 101, 2999, 10.1073/pnas.0307323101 · DOI
  94. Meijer, 2009, MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression, Br J Cancer, 101, 707, 10.1038/sj.bjc.6605037 · DOI
  95. Zhang, 2013, MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer, Oncogene, 32, 1910, 10.1038/onc.2012.214 · DOI
  96. Lyko, 2007, The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function, Cancer Res, 67, 1419, 10.1158/0008-5472.CAN-06-4074 · DOI
  97. Caldas, 2007, Genetic unmasking of an epigenetically silenced microRNA in human cancer cells, Cancer Res, 67, 1424, 10.1158/0008-5472.CAN-06-4218 · DOI
  98. Fritz, 2008, Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer, Oncogene, 27, 3880, 10.1038/onc.2008.10 · DOI · Paper page
  99. Hermeking, 2008, Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer, Cell Cycle, 7, 2591, 10.4161/cc.7.16.6533 · DOI
  100. Nojima, 2014, MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation, colorectal continuum in serrated lesions, Int J Cancer, 135, 2507, 10.1002/ijc.28920 · DOI
  101. Wolff, 2011, MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype, Genes Chromosomes Cancer, 50, 196, 10.1002/gcc.20844 · DOI
  102. Mendell, 2014, An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration, Cell, 157, 1104, 10.1016/j.cell.2014.03.055 · DOI
  103. Hofacker, 2007, How microRNAs choose their targets, Nat Genet, 39, 1191, 10.1038/ng1007-1191 · DOI
  104. Sander, 2013, Analysis of microRNA-target interactions across diverse cancer types, Nat Struct Mol Biol, 20, 1325, 10.1038/nsmb.2678 · DOI
  105. Nusse, 2014, Stem cell signaling, An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science, 346, 1248012
  106. Lynch, 2004, Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis, Am J Gastroenterol, 99, 681, 10.1111/j.1572-0241.2004.04115.x · DOI
  107. Nakamura, 1992, Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene, Hum Mol Genet, 1, 229, 10.1093/hmg/1.4.229 · DOI
  108. Agami, 2008, Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer, Cancer Res, 68, 5795, 10.1158/0008-5472.CAN-08-0951 · DOI
  109. Sumani, 2014, MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer, Cancer Cell, 25, 469, 10.1016/j.ccr.2014.03.006 · DOI
  110. Clevers, 2006, Wnt/beta-catenin signaling in development and disease, Cell, 127, 469, 10.1016/j.cell.2006.10.018 · DOI · Paper page
  111. Hermeking, 2011, Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis, Mol Cell Proteomics, 10
  112. Akao, 2013, Tumor-suppressive microRNA-145 targets catenin delta-1 to regulate Wnt/beta-catenin signaling in human colon cancer cells, Cancer Lett, 335, 332, 10.1016/j.canlet.2013.02.060 · DOI
  113. Odenthal, 2011, Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy, Int J Oncol, 39, 409
  114. Hoefler, 2012, Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer, Br J Cancer, 106, 1826, 10.1038/bjc.2012.175 · DOI
  115. Dong, 2014, Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy, Anticancer Drugs, 25, 346, 10.1097/CAD.0000000000000049 · DOI
  116. Andersen, 2012, Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes, Oncogene, 31, 2750, 10.1038/onc.2011.453 · DOI
  117. Kang, 2012, Genome-wide identification of TCF7L2/TCF4 target miRNAs reveals a role for miR-21 in Wnt-driven epithelial cancer, Int J Oncol, 40, 519
  118. Kim, 2013, p53 regulates nuclear GSK-3 levels through miR-34-mediated Axin2 suppression in colorectal cancer cells, Cell Cycle, 12, 1578, 10.4161/cc.24739 · DOI
  119. Lee, 2011, p53 and microRNA-34 are suppressors of canonical Wnt signaling, Sci Signal, 4, ra71
  120. Goel, 2012, Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family, Carcinogenesis, 33, 2441, 10.1093/carcin/bgs286 · DOI
  121. Thomas-Tikhonenko, 2010, The myc-miR-17∼92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors, Cancer Res, 70, 8233, 10.1158/0008-5472.CAN-10-2412 · DOI
  122. Kitano, 2005, A comprehensive pathway map of epidermal growth factor receptor signaling, Mol Syst Biol, 1, 1
  123. Van Den Brandt, 2003, K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study, Carcinogenesis, 24, 703, 10.1093/carcin/bgg009 · DOI
  124. Mayer, 2004, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor, J Clin Oncol, 22, 1201, 10.1200/JCO.2004.10.182 · DOI · Paper page
  125. Tabernero, 2015, Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer, Am Soc Clin Oncol Educ Book, 35, e149
  126. Slack, 2005, RAS is regulated by the let-7 microRNA family, Cell, 120, 635, 10.1016/j.cell.2005.01.014 · DOI
  127. Van Engeland, 2011, A let-7 microRNA SNP in the KRAS 3′UTR is prognostic in early-stage colorectal cancer, Clin Cancer Res, 17, 7723, 10.1158/1078-0432.CCR-11-0990 · DOI
  128. Harris, 2012, KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter, Clin Cancer Res, 18, 3487, 10.1158/1078-0432.CCR-12-0250 · DOI
  129. D'emidio, 2010, Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan, Pharmacogenomics J, 10, 458, 10.1038/tpj.2010.9 · DOI
  130. Diasio, 2014, Association study of the let-7 miRNA-complementary site variant in the 3′ untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial), Clin Cancer Res, 20, 3319, 10.1158/1078-0432.CCR-14-0069 · DOI
  131. Piessevaux, 2014, A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy, Clin Cancer Res, 20, 4499, 10.1158/1078-0432.CCR-14-0348 · DOI
  132. Yang, 2009, Role of miR-143 targeting KRAS in colorectal tumorigenesis, Oncogene, 28, 1385, 10.1038/onc.2008.474 · DOI
  133. Kwok, 2009, The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras, Carcinogenesis, 30, 953, 10.1093/carcin/bgp094 · DOI
  134. Doki, 2015, Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer, Mol Ther Nucleic Acids, 4, e231, 10.1038/mtna.2015.5 · DOI
  135. Yu, 2013, Tumor suppressor functions of miR-133a in colorectal cancer, Mol Cancer Res, 11, 1051, 10.1158/1541-7786.MCR-13-0061 · DOI
  136. Lothe, 2015, Portrait of the PI3K/AKT pathway in colorectal cancer, Biochim Biophys Acta, 1855, 104
  137. Messersmith, 2012, Common PIK3CA mutants and a novel 3′ UTR mutation are associated with increased sensitivity to saracatinib, Clin Cancer Res, 18, 2704, 10.1158/1078-0432.CCR-11-3167 · DOI
  138. Abbruzzese, 2015, Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer, Invest New Drugs, 33, 977, 10.1007/s10637-015-0257-z · DOI
  139. Guda, 2008, The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers, Genes Chromosomes Cancer, 47, 939, 10.1002/gcc.20596 · DOI
  140. Wu, 2013, miR-30a suppresses cell migration and invasion through downregulation of PIK3CD in colorectal carcinoma, Cell Physiol Biochem, 31, 209, 10.1159/000343362 · DOI
  141. Longy, 2000, Mutations of the human PTEN gene, Hum Mutat, 16, 109, 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0 · DOI
  142. Michael, 2013, Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster, Mol Carcinog, 52, 459, 10.1002/mc.21879 · DOI
  143. Struhl, 2010, STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer, Mol Cell, 39, 493, 10.1016/j.molcel.2010.07.023 · DOI · Paper page
  144. Zhou, 2013, MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells, Mol Cancer, 12, 30, 10.1186/1476-4598-12-30 · DOI
  145. Privitera, 2012, Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors, J Mol Med (Berl), 90, 1421, 10.1007/s00109-012-0918-8 · DOI
  146. Attardi, 2014, Unravelling mechanisms of p53-mediated tumour suppression, Nat Rev Cancer, 14, 359, 10.1038/nrc3711 · DOI
  147. Harris, 1991, p53 mutations in human cancers, Science, 253, 49, 10.1126/science.1905840 · DOI · Paper page
  148. Ju, 2006, Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer, Clin Cancer Res, 12, 2014
  149. Hermeking, 2007, Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest, Cell Cycle, 6, 1586, 10.4161/cc.6.13.4436 · DOI
  150. Tokino, 2008, Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer, Cancer Res, 68, 4123, 10.1158/0008-5472.CAN-08-0325 · DOI
  151. Naoe, 2011, Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells, Cancer Lett, 300, 197, 10.1016/j.canlet.2010.10.006 · DOI
  152. Lowenstein, 2008, miR-34a repression of SIRT1 regulates apoptosis, Proc Natl Acad Sci U S A, 105, 13421, 10.1073/pnas.0801613105 · DOI
  153. Dobbelstein, 2008, p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest, Cancer Res, 68, 10094, 10.1158/0008-5472.CAN-08-1569 · DOI
  154. Mori, 2011, MicroRNA miR-125b is a prognostic marker in human colorectal cancer, Int J Oncol, 38, 1437, 10.3892/ijo.2011.969 · DOI
  155. Feng, 2014, MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling, Oncotarget, 5, 9106, 10.18632/oncotarget.2379 · DOI
  156. Lal, 2012, MicroRNAs, wild-type and mutant p53: more questions than answers, RNA Biol, 9, 781, 10.4161/rna.20146 · DOI
  157. Heldin, 2009, The regulation of TGFbeta signal transduction, Development, 136, 3699, 10.1242/dev.030338 · DOI
  158. Grady, 2008, Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells, Genes Chromosomes Cancer, 47, 95, 10.1002/gcc.20511 · DOI
  159. Pasche, 2010, Tgf-beta signaling alterations and colon cancer, Cancer Treat Res, 155, 85, 10.1007/978-1-4419-6033-7_5 · DOI
  160. Majumdar, 2012, MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells, Carcinogenesis, 33, 68, 10.1093/carcin/bgr246 · DOI
  161. Zheng, 2012, Colorectal cancer migration and invasion initiated by microRNA-106a, PLoS One, 7, e43452, 10.1371/journal.pone.0043452 · DOI
  162. Han, 2013, The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression, PLoS One, 8, e55532, 10.1371/journal.pone.0055532 · DOI
  163. Wan, 2013, MiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3, PLoS One, 8, e70300, 10.1371/journal.pone.0070300 · DOI
  164. Zheng, 2012, Rho GTPase regulation by miRNAs and covalent modifications, Trends Cell Biol, 22, 365, 10.1016/j.tcb.2012.04.004 · DOI
  165. Bi, 2011, miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells, Cancer Lett, 301, 151, 10.1016/j.canlet.2010.11.009 · DOI
  166. Deng, 2011, miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells, Int J Cancer, 128, 1269, 10.1002/ijc.25452 · DOI
  167. Jakobsen, 2011, Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer, Oncol Lett, 2, 1101, 10.3892/ol.2011.372 · DOI
  168. Rossi, 2012, High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease, Oncologist, 17, 823, 10.1634/theoncologist.2012-0081 · DOI
  169. Adachi, 2014, Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer, Ann Surg Oncol, 22, 2640
  170. Dvorak, 2008, Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer, Int J Oncol, 33, 541
  171. Gaedcke, 2013, Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g, Radiother Oncol, 108, 451, 10.1016/j.radonc.2013.06.032 · DOI
  172. Kerin, 2013, miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy, Int J Colorectal Dis, 28, 247, 10.1007/s00384-012-1549-9 · DOI
  173. Yang, 2014, MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression, Oncotarget, 5, 2974, 10.18632/oncotarget.1614 · DOI
  174. Li, 2011, Increased expression of microRNA-21and its association with chemotherapeutic response in human colorectal cancer, J Int Med Res, 39, 2288, 10.1177/147323001103900626 · DOI
  175. Sasaki, 2014, High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer, Int J Cancer, 134, 1926, 10.1002/ijc.28522 · DOI
  176. De La Portilla, 2014, MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer, BMC Cancer, 14, 656, 10.1186/1471-2407-14-656 · DOI
  177. Pepe, 2012, A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer, Int J Radiat Oncol Biol Phys, 83, 1113, 10.1016/j.ijrobp.2011.09.030 · DOI
  178. Jakobsen, 2014, Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer, Mol Cancer Ther, 13, 2238, 10.1158/1535-7163.MCT-14-0131 · DOI
  179. Liu, 2013, MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers, Cell Cycle, 12, 1385, 10.4161/cc.24477 · DOI
  180. Goel, 2012, The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer, PLoS One, 7, e46684, 10.1371/journal.pone.0046684 · DOI
  181. Xu, 2012, MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer, Int J Cancer, 131, 1042, 10.1002/ijc.26485 · DOI
  182. Wang, 2013, Multi-microarray identifies lower AQP9 expression in adjuvant chemotherapy nonresponders with stage III colorectal cancer, Cancer Lett, 336, 106, 10.1016/j.canlet.2013.04.017 · DOI
  183. Goldin, 2014, The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer, Colorectal Dis, 16, O133, 10.1111/codi.12482 · DOI
  184. Pelicano, 2014, Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression, Hepatology, 60, 598, 10.1002/hep.27118 · DOI
  185. Ju, 2010, Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells, Mol Cancer, 9, 96, 10.1186/1476-4598-9-96 · DOI
  186. Slaby, 2012, MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients, Radiat Oncol, 7, 195, 10.1186/1748-717X-7-195 · DOI
  187. Xiong, 2015, miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1, Biochem Biophys Res Commun, 457, 125, 10.1016/j.bbrc.2014.11.039 · DOI
  188. Garcia-Foncillas, 2011, MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells, Stem Cells, 29, 1661, 10.1002/stem.741 · DOI
  189. Pfeiffer, 2013, High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer, Mol Oncol, 7, 637, 10.1016/j.molonc.2013.02.016 · DOI
  190. Rugge, 2011, PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis, Virchows Arch, 458, 413, 10.1007/s00428-011-1046-5 · DOI
  191. Tsutsumi, 2009, Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development, Clin Cancer Res, 15, 4009, 10.1158/1078-0432.CCR-08-3257 · DOI
  192. Marohn, 2011, Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning, Endocr Relat Cancer, 18, 465, 10.1530/ERC-11-0083 · DOI
  193. Shu, 2014, MicroRNAs as promising biomarkers for tumor-staging: evaluation of MiR21 MiR155 MiR29a and MiR92a in predicting tumor stage of rectal cancer, Asian Pac J Cancer Prev, 15, 5175, 10.7314/APJCP.2014.15.13.5175 · DOI
  194. Fang, 2014, miR-194 as a predictor for adenoma recurrence in patients with advanced colorectal adenoma after polypectomy, Cancer Prev Res (Phila), 7, 607, 10.1158/1940-6207.CAPR-13-0426 · DOI
  195. Kang, 2015, Paired design study by real-time PCR: miR-378* and miR-145 are potent early diagnostic biomarkers of human colorectal cancer, BMC Cancer, 15, 158, 10.1186/s12885-015-1123-2 · DOI
  196. Jakobsen, 2014, Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohort, Br J Cancer, 111, 1285, 10.1038/bjc.2014.409 · DOI
  197. Croce, 2008, MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma, JAMA, 299, 425
  198. Harris, 2009, Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma, Clin Cancer Res, 15, 5878, 10.1158/1078-0432.CCR-09-0627 · DOI
  199. Cai, 2013, Prognostic role of microRNA-21 in colorectal cancer: a meta-analysis, PLoS One, 8, e80426, 10.1371/journal.pone.0080426 · DOI
  200. Xu, 2014, Diagnostic and prognostic value of microRNA-21 in colorectal cancer: an original study and individual participant data meta-analysis, Cancer Epidemiol Biomarkers Prev, 23, 2783, 10.1158/1055-9965.EPI-14-0598 · DOI

200 of 296 shown

Cited by

Sorted by citations

Metadata

Authors
Cekaite, L., Eide, P. W., Lind, G. E., Skotheim, R. I., & Lothe, R. A.
Affiliations
Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
Venue
Oncotarget
Published
2015-11-25
Volume
7
Issue
6
Pages
6476-6505
ISSN
1949-2553
Cited by
84
References
6
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review